Background: A newly developed, anodized titanium oxide surface containing anatase has been reported to have antimicrobial properties that could reduce bacterial adherence to abutments.
abutments at the 6-week follow-up. Secondary endpoints included several soft tissue assessments. qPCR for gene markers was used to indirectly evaluate healing and soft tissue health.
Results: No significant differences in biofilm formation were observed between test and control abutments, but soft tissue bleeding upon abutment removal was significantly lower for test abutments compared with control abutments (P = 0.006) at 6 weeks. Keratinized mucosa height was significantly greater at test abutments compared with control abutments at the 6-week, 6-month, and 2-year follow-ups. Significant gene expression differences indicated differences in healing and tissue remodeling.
Conclusions:
Abutments with an anodized and nanostructured surface compared with a conventional, machined titanium surface had no significant effect on bacterial colonization and proteolytic activity but were associated with better soft tissue outcomes such as a lower bleeding index at abutment removal and consistently greater height of keratinized mucosa throughout the 2-year follow-up, suggesting improved surface-dependent peri-implant healing and soft tissue health.
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| INTRODUCTION
For the past 40 years, dental implant treatment has been used to replace lost or missing teeth to provide for successful oral rehabilitation. However, the treatment has, in some cases, resulted in complications, and suboptimal peri-implant soft tissue health and/or bone loss.
Such complications often commence with inflammation of the soft tissue surrounding the abutment. It has been proposed that the risk for inflammation could be reduced by placing abutments in firm tissue with minimal mobility, [1] [2] [3] [4] [5] and it is clinical practice to place abutments embedded in keratinized mucosa whenever possible. Keeping inflammation sufficiently low is necessary to allow for optimized integration of the abutments in soft tissue and to avoid perturbation of tissue structure recovery during the healing phase after abutment placement. Initial firm soft tissue integration (ie, tissue stability of surrounding mucosa that is closely juxtaposed to the abutment with low mucosa mobility obtained during healing) may also increase the probability of maintaining soft tissue health in the long term. [1] [2] [3] [4] [5] After placing an implant abutment that emerges through the mucosa, the surface immediately becomes covered with a pellicle of ions and proteins derived mainly from serum and saliva, where the composition of the pellicle is determined by presence of available adsorbents and surface properties such as topography, micro-and nanostructured morphology, chemistry and possible crystallinity.
Adsorbed ions and proteins, combined with the underlying substrate surface, then provide the conditions (cell proliferation and migration, wound healing, collagen expression, keratinized tissue formation) that result in soft tissue integration. However, these ions and proteins also offer a range of binding sites for oral bacteria to attach and initiate the development of a microbial biofilm. The microbial activity within the biofilm and the host response to such activity is usually balanced to preserve tissue health, but the balance may sometimes be shifted toward tissue degradation. One approach to prevent such a shift is to modify the abutment surface in a manner that reduces biofilm formation and promotes rapid soft tissue healing and soft tissue integration.
Because roughened surfaces have been demonstrated to increase plaque formation in vivo, 6 "smooth" surfaces with roughness values smaller than the "critical threshold" of Sa = 0.2 μm (arithmetical mean height) 7 are often preferred for abutments.
Titanium-based metals are always covered with a thin layer of titanium oxide, and one of its crystalline structures, anatase, has shown antibacterial effects in vitro, both in combination with and absence of ultraviolet (UV) radiation. [8] [9] [10] In vitro studies performed by Dorkhan et al 11 showed that a modified titanium oxide surface comprising anatase could reduce bacterial adherence in absence of UV radiation while providing for good human cell attachment. The modified surface used by Dorkhan et al was manufactured using anodic oxidation, was nanostructured and had the same machined structure at the micrometer level as the control surface with a surface roughness at the critical threshold of Sa = 0.2 μm. 7 No compounds or materials were added to the modified surface. The in vitro data demonstrated significantly lower adherence of some early bacterial colonizers but similar adherence of fibroblasts and keratinocytes on the modified surface compared with a machined control surface. 11 It was also shown that early colonizing bacteria caused cell damage of keratinocytes. 12 Therefore, abutments with a surface of the type studied by Dorkhan et al may inhibit the presence of cell damaging bacteria and thus promote cell proliferation and migration, wound healing, keratinized tissue formation and improved tissue health in vivo.
The main objective of this prospective, controlled clinical study was to investigate if and how the new, modified implant abutment surface studied by Dorkhan et al allowed for improved soft tissue healing and health compared with the machined control abutment surface used on commercial abutments.
| MATERIALS AND METHODS
This report follows the CONSORT guidelines for randomized trials (http://www.consort-statement.org).
| Study design
This randomized clinical trial was conducted at a single facility, the The first part of the study including the 6-week follow-up at retrieval of the test and control abutment was completed in 7 months. The 6-month follow-up after placement of the permanent test and control abutment was completed after an additional 7 months in January 2016.
The 2-year follow-up started in February 2017 and was completed in
June 2017. The follow-up intervals were 6 weeks ± 1 week, 6 months ± 6 weeks, and 2 years ± 4 months.
| Subjects
Subjects scheduled for treatment with two or more implants were asked to join this study if they fulfilled the following inclusion criteria: 
| Surgery and postoperative care
Two implant sites per subject were selected for the study. The test and control implants were both placed in either the mandible or maxilla, where the sites were similar with respect to soft tissue and bone properties in each patient as judged by the principal investigator. Specifically, implant sites were sought to resemble each other in terms of available bone height, bone width (to allow for placement of at least a 3.75 mm diameter implant), and the surrounding soft tissue contours.
The implants that were used were Brånemark System Mk III, TiUnite, or Mk IV, TiUnite, Nobel Biocare AB, Göteborg, Sweden. Sizes were selected depending on the clinical situation: Diameters: 3.75 mm (RP), 4.0 mm (RP), and 5.0 mm (WP). Lengths: 8.5 mm, 10 mm, 11.5 mm, 13 mm, and 15 mm. All study implants were placed during one-stage open flap surgery, with the implant-abutment junction at the marginal bone crest level in mandible or maxilla. The drilling protocol followed the manufacturer's recommendations for the Brånemark System implants. Specifically, for the regular platform (RP) implants a 2-mm diameter twist drill was used to the estimated depth, followed by a step drill (diameter 2.4-2.8 mm) and a 3-mm diameter twist drill.
Finally, a counterbore opened up the site for the implant head. For the wide-platform (WP) implant site preparations, the aforementioned counterbore was omitted to be replaced with a step drill diameter 3.2 to 3.6 mm and a step drill 3.8 to 4.2 mm, finally followed by a wider counterbore. No deviations from these protocols were registered and the final insertion torque was between 30 and 50 Ncm. The abutments originally placed at implant insertion were replaced by abutments with the same surface properties 6 weeks after implant placement, and the subjects were thereafter scheduled for follow-up after 6 months and 2 years. Standard straight and angulated multi-unit abutments (Nobel Biocare AB) were used. All abutments were manufactured, packaged, labeled and gamma sterilized by Nobel Biocare according to standard operation procedures.
| Abutments
All abutments used in this study were CE marked. They were made of commercially pure titanium (straight multi-unit abutments) or TiAl 6 V 4 titanium alloy (angulated multi-unit abutments), and designed to have the same surface properties as the surfaces used by Dorkhan et al.
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The new surface was modified by anodic oxidation resulting in an approximately 100 nm thick titanium oxide layer with nanostructures <100 nm. The surface structure made by machining, that is, turning, when manufacturing the abutments, was preserved after anodization, and the surface roughness (Sa) was approximately 0.2 μm for both test and control surfaces. The modified surface was yellow due to light interference within the titanium oxide whereas the control surface was gray. 14 The abutments used during the first 6 weeks after implant placement were standard machined commercially pure titanium straight multi-unit abutments with polymer healing cap for external hex connection; Brånemark System, regular platform (RP) and wide platform (WP) and height RP: 1, 2 and 3 mm, height WP: 1 and 2 mm.
Test abutments had the new, modified titanium oxide surface. The abutments used after retrieval of the abutment placed at surgery were same as the test or the control abutment used before with the healing cap. In addition, multi-unit abutments with 17 angulation and of lengths 2 and 3 mm were used in some cases.
Implants were inserted, connected with respective test and control abutment, and subjects asked to refrain from using their prostheses up until suture removal after 7 to 10 days. Prostheses were then adjusted by preparation of the acrylic material and placing a soft tissue conditioner to fit on top of the abutments/healing caps. Occlusion was rigorously evaluated to allow for proper load distribution.
2.5 | Abutment retrieval and placement of permanent restoration The abutments placed at surgery were replaced by new, multiunit abutments. The new test and control abutments were connected, healing caps attached, and the rehabilitation with fixed prostheses commenced. The subjects were given instructions on how to maintain oral hygiene after placement of permanent abutments.
| Microbiological analyses
Biofilms were removed from the control and test abutments using a Quickstick (Dab Dental AB, Upplands Väsby, Sweden), suspended in 350 μL prereduced dilution medium, and processed for further analysis. 13 The cultivable microflora (CFU) in the sample was evaluated by culturing on prereduced Brucella agar. Two hundred μL of the sample was serially diluted in reduced PBS and 200 μL of each dilution plated on Brucella agar and distributed evenly. Plates were incubated at 37 C under anaerobic conditions for 10 days.
Total proteolytic activity (Relative Fluorescence Units, RFU) at the retrieved abutments was assessed using FITC-labeled casein (QuantiCleave Fluorescent Protease Assay kit, Pierce) as a substrate as previously described. 14 
| Collection of peri-implant cervical fluid (PICF) samples
Peri-implant crevicular fluid (PICF) was sampled and analyzed at all three follow-up visits. The procedure has been reported previously. 15 The PICF samples were collected using three sterile paper points (Roeke, Coltene, Germany) inserted to the base of the peri-implant sulcus/ pocket and left in situ for at least 60 seconds. The three paper points were immediately transferred to one 2 mL plastic tube (Microtube, 2 mL, Sarstedt, Numbrecht, Germany) containing RNALater preservation medium (Qiagen, Hilden, Germany); i.e. the three samples were pooled. Clean gloves were always used when handling the tubes. The pooled sample was transported for gene expression analysis to Tataa
Biocenter AB (Göteborg, Sweden). The samples were kept in a refrigerator for less than a week before extraction from the paper points for analysis.
| Gene expression analysis by qPCR
The following gene markers were analyzed: three proteases expressed by bacteria: serine peptidase (soHtrA), which is a serine protease from high abundance relative to the other assays, since it would have biased the performance of the preamplification. The preamplification performance was validated according to the method previously described. 16 Quantitative polymerase chain reaction (qPCR) assays of the samples were then performed.
Relative gene expression levels were calculated using the ΔΔCt method 17 using 90% efficiency for each assay and by normalizing gene expression of each gene using the average mean of the following house-keeping genes: YWHAZ and UBC. The selection of normalization genes was based on results from two of our previous studies, 15, 18 using the same sampling and analysis technique except for the preamplification step.
| Primary outcome measures
The primary outcome measure was reduction of biofilm formation at the test abutments compared with the control abutments at the 6-week follow-up (null hypothesis: mean CFU is the same at test and control abutments). Biofilm formation and the degradation activity of the biofilm adhering to the retrieved abutments were quantified with respect to colony forming units and proteolytic activity.
| Soft tissue assessments used for the secondary outcome measures
Bleeding at the site after abutment retrieval was assessed immediately after the abutment had been removed. The extent of bleeding was assessed as bleeding index on abutment retrieval using a scale from 0 to 3 with steps of 0.5, where 0 = no bleeding, 1 = isolated bleeding spots visible, 2 = a homogenous pool of blood formed at the soft tissue surface, and 3 = heavy or profuse bleeding.
Improved healing and soft tissue health at the test compared to the control abutments were demonstrated if the following were shown in relation to test abutments:
• a lower bleeding index on abutment retrieval at the 6-week follow-up as well as a lower score for bleeding on probing (BoP) (scale 0-3) when a probe was gently passed around the abutment according to Mombelli et al 19 at the 6-month and 2-year followups and/or;
• the keratinized mucosa (in mm) was higher when measured on the buccal side using a probe and/or;
• the soft tissue redness and swelling index was lower (0 = no redness or swelling, 1 = mild redness visible, 2 = significant redness and/or swelling, 3 = strong redness and/or swelling) and/or;
• plaque accumulation was less, as assessed using the modified Plaque Index (mPI) (scale 0-3) according to Mombelli et al 19 and/or;
• the incidence of suppuration at implant sites was lower when tested by probing of the peri-implant tissues using light pressure.
Ancillary measurements were the height of mucosa in the soft tissue cavity in mm after abutment retrieval and peri-implant probing depth (PIPD) at the 6-month and 2-year follow-ups measured using a periodontal probe (PH6 Colorvue Probe, Hu-Friedy, Chicago, IL). Soft tissue position in relation to the restoration margin was measured in mm using a probe at all-time points.
| Exploratory analysis of additional ("non-study") abutments
Several subjects received more than the two implants and abutments used in the study, and abutments with the control surface type were placed at these additional sites. The height of keratinized mucosa at such abutments was measured in an exploratory analysis, and the average keratinized mucosa height at these sites in each subject was compared with the keratinized mucosa height at the test and control abutments of the respective subject at the 6-month and 2-year followup. This exploratory analysis was designed to test the hypothesis (a) whether the height of the keratinized mucosa at these additional control-type abutments was comparable with the height at the control abutments that were part of the study's split-mouth design, and (b) whether the difference in the height of keratinized mucosa at test and control abutments also can be detected between the test and the additional control-type abutments that were not part of the split-mouth design.
| Radiographic assessment
Digital images were taken from all test and control abutments at all follow-up visits. Peri-implant bone levels were assessed using intra-oral radiographs. Standardized intra-oral digital radiographs were obtained using a parallel technique. All images were interpreted by an independent radiologist. Radiographs were displayed in Sectra IDS7 PACS (Sectra Imtec AB, Linköping, Sweden) or in Planmeca Romexis (Planmeca Oy, Helsinki, Finland) on a 20-in. monochromatic screen (OLORIN Medic Line ML 187D TFT-LCD; Olorin AB, Kungsbacka Sweden). The screen resolution was 1280 × 1024 pixels. The measuring tool in the Sectra IDS7
PACS software was employed for the measurements.
Marginal bone levels were determined by measuring the distance to the nearest 0.1 mm between the interproximal marginal bone and a predetermined reference point (defined as the fixture-abutment junction) on both the mesial and distal surfaces for each implant. The mean of these two measurements was used to represent the marginal bone level for each implant after placement of permanent prosthetic constructions and at the 2-year follow-up.
The follow-up schedule for each outcome measurement is given in Table 1 .
In addition, safety parameters were monitored and evaluated by clinical observation and assessment of radiographs. Spontaneous reports of adverse events and serious adverse events were recorded.
| Sample size calculation
Data on biofilm formation on conventional (control) abutments taken from four subjects was available from previous analyses at the Brånemark Clinic (not published). It was used for power calculation.
The SD of the difference of the logarithm (base 2) of CFU per mL in dilution medium at two abutments with the control surface type in the same subject was estimated to 0.4829. Assuming the same SD and an intended change of 0.25 in logarithm (base 2) of CFU, corresponding to a 16% decrease in CFU per mL, between the test and the control surface with Fisher's nonparametric permutation test for paired observations, 31 evaluable subjects were needed. Assuming a 13% withdrawal rate, 35 patients were included. Subjects withdrawn from the study were not replaced.
| Randomization
Abutment positions within each subject were randomized with respect to abutments with the new, modified test and the control surface using the SAS software (SAS System Version 9, SAS Institute, Cary, NC). A randomization scheme was read by an assistant out to the principal investigator immediately before abutment insertion.
| Blinding
The principal investigator and two co-workers performed the surgical procedures, clinical assessment and PICF sampling; the principal investigator, co-workers and persons involved in the microbial analyses
were not blinded to the abutment surface type, since the test surface was yellow and the control surface was gray. All persons involved in the analyses of the PICF samples, radiographs and statistical analyses were blinded.
| Statistical methods
All statistical analyses were made for paired abutments within sub- 
| RESULTS
Thirty-five subjects with a mean age of 69 years and comprising 60% females were enrolled in the study ( Table 2 ). The subjects' baseline data, medical conditions, medication history and oral hygiene represented the normal population scheduled for implant treatment at the Brånemark Clinic. Twenty-five subjects (71.4%) had compromised Marginal bone level was measured after the subjects had received the permanent prosthetic construction, which varied between 0.5 and 9.5 months. Some subjects received additional implants with two-stage surgery, which were left submerged several months to allow for osseointegration.
health, where the most common health conditions comprised high blood pressure (11) , cardiovascular disease (8), depression (6) and allergy (5) . During the study period, 2 subjects (5.7%) died and the health condition changed for 12 subjects (34.3%), comprising kidney pain, lung problems, cancer, knee operations, cardiovascular problems, stomach problems, osteoporosis, spinal stenosis, and cataract operation. None of these events was considered related to the materials or procedures used in this study.
Nine subjects (25.7%) were withdrawn from the study (Figure 1) for the following reasons: Two subjects were withdrawn due to incomplete osseointegration and insufficient implant stability at 6-week follow-up, and no data from these subjects were used in the analyses. One subject with a history of lung problems was hospitalized for treatment. Two subjects experienced pain on abutment removal, indicating lack of sufficient osseointegration, and data from these two subjects were used in the 6-week follow-up analyses only. Two subjects moved to another location and did not attend the 6-month visit.
One subject could not attend within the 6 months ±6 weeks followup interval and one could not attend within the 2 years ±4 months follow-up interval.
Thirty-five pairs of abutments were placed. Thereof, 15 (43%)
were placed in the maxilla and 20 (57%) in the mandible. In full maxillae the most frequent test and control sites were FDI positions 11 and 21 or in full mandibles FDI positions 34 and 44. In patients who only required two implants for a partial fixed prosthesis the implants were placed close to each other, and in three of those patients (posterior , P = 0.28) ( Table 3) .
Three pairs were excluded from the microbial analysis due to saliva contamination stemming from handling in the clinical setting. Mean total proteolytic activity was similar and not statistically different between the two abutment surfaces (P = 0.66).
At 6-week follow-up, mean soft tissue bleeding upon removal of the test abutments was significantly lower compared with the control abutments (0.6 vs 1.1, P = 0.006) ( Figure 2A -C).
The exploratory analysis of control-type abutments that were placed in addition to the pair of test and control abutments for this study included 17 subjects at the 6-month and 20 subjects at the 2-year follow-up (Table 4) . Mean heights of the keratinized mucosa at study control abutments and additional control-type abutments were similar at 6-month (2.29 mm vs 2.04 mm, P = 0.29) and 2-year followup (2.05 mm vs 1.79 mm, P = 0.23). At test abutments, the mean height of keratinized mucosa was significantly higher when compared with the height at additional control-type abutments (6-month followup: 2.68 mm vs 2.04 mm, P = 0.026; 2-year follow-up: 2.40 mm vs 1.79 mm, P = 0.022).
There were no significant differences between the test and control surfaces with respect to plaque index and signs of inflammation (Table 3) . Large plaque accumulation, plaque index 3, was not registered at any of the abutments. No signs of significant inflammation were recorded at any of the abutments at the 6-week, 6-month, and 2-year follow-up. Suppuration was not detected at any abutment at any time.
The mucosa height was 2 mm (SD = 0.9 mm) at both the test and control abutments when measured in the mucosa cavity after removal of the abutments.
No significant differences of peri-implant probing depth at sites of the test and control abutments were detected ( Table 3) .
The restoration margin, that is, the facial soft tissue position in relation to the interface between the titanium abutment and the polymer cap, was not significantly different between the two types of abutment surfaces at abutment insertion as well as the 6-month and 2-year follow-up (Table 3) .
Radiographic measurements showed no significant differences of bone levels at the test and control abutments within subjects at any time. After the permanent prosthetic construction was placed, marginal bone levels were the same, −1.8 mm measured from the implant abutment junction, at the test (SD = 0.8 mm) and control (SD = 0.6 mm)
abutments. At the 2-year follow-up, marginal bone levels were −1.8 mm (SD = 0.8 mm) and −2.1 mm (SD = 0.9 mm) for the test and control abutments, respectively (P = 0.15). Twenty and 16 subjects with test and control abutments, respectively, had bone level changes of -(0-2) mm at this time point. Four subjects with test abutments and 5 subjects with control abutments hade changes between -(2-3) mm. One and four subjects with test and control abutments, respectively, had changes between -(3-4) mm and one subject with the test and one subject with the control abutment had a bone level change between -(4-5) mm.
mRNA expression analysis showed abundant expression of bacterial 16S mRNA without significant difference between sites at test and control abutments at all time-points ( Table 5 ). Transcripts of bacterial serine peptidase (soHtrA, Fusobacterium nucleatum) were detected in some subjects (5-17 depending on group and visit) without significant difference between the two abutment surfaces. Metalloprotease from P. intermedia (pilA) and gingipain from P. gingivalis (pgKgp) were only detected in few subjects, which was insufficient for statistical analyses. Among human genes tested for mRNA expression, tissue plasminogen activator at the 6-week follow-up and collagen IV at 6-month follow-up were significantly up-regulated in PICF from test vs control abutments. Osteocalcin at 6-week and 2-year followup and TIMP-1 expression was down-regulated at test vs control abutments at 6-month follow-up.
| DISCUSSION
Mean CFUs in biofilms at test abutments were four times lower than at control abutments; however, the difference was not statistically significant due to unexpected high SDs. Such a situation may indicate an underpowered study; the power calculation for the design of this study was based on previous analyses of biofilm formation data from eight conventional (control) abutments in four subjects that were available at the Brånemark Clinic (not published). However, in contrast to the relatively narrow SD of CFU in the previous analyses, the CFUs recorded in the study presented here included more extreme values. Also, quantitative analysis of bacterial 16S mRNA showed abundant bacterial colonization over time without significant difference between the abutment types.
In contrast to the null hypothesis (mean CFU is the same at test and control abutments), the microbial consortia in the biofilm and excretion of bacteria-specific proteases may have a stronger influence on soft tissue healing and clinical outcome around implants and abutments than just the number of bacteria present at a site. While the total proteolytic activity was rather evenly distributed and not significantly different between samples from the abutment sites, the mRNA expression of tested bacteria-specific serine-and metalloproteases was very heterogenous across both the test and the control sites.
However, the number of sites with positively detected expression was too low for meaningful statistical analyses. Further studies investigating the patterns of bacterial composition and actually secreted proteases may provide additional useful information. The presence of mild inflammation at only a few test and control sites, ≤3 respectively, and the measured significant differences and improvements in bleeding as discussed above indicate that assessment of bleeding by removing the abutments and by passing a probe were more sensitive to the soft tissue health status than ocular assessment of inflammation at the abutment sites. Height of keratinized gingiva has been associated with periodontal health, where a low keratinized gingiva, usually ≤2 mm, has been found to increase the probability for suboptimal periodontal tissue health conditions such as inflammation and bleeding, whereas a high keratinized gingiva has often been associated with an increased probability for maintaining good periodontal health. Cross-sectional studies on the relationship between keratinized gingiva height and periodontal tissue health have been reported, and a similar relationship between mucosa height and tissue health at implant abutments has been reported by several groups. [1] [2] [3] [4] [5] Thus, it seems likely that a high keratinized mucosa, which is often associated with low peri-implant/ abutment tissue mobility, would also increase the probability for healthy peri-implant tissue at abutments. While the presence and amount of keratinized mucosa seems to be favorable for good clinical outcomes, it may not be an absolute requirement as reported by Wennström et al, who found no significant differences in the clinical parameters between sites with and without an "adequate" width of keratinized mucosa. 22 Conversely, a more recent systematic review and meta-analysis of 11 studies showed favorable effects of wide keratinized mucosa on outcomes of plaque index, modified gingival index, mucosal recession, and attachment loss. 3 While Lin et al found no statistically significant effect on bleeding index and BoP, a later published cross-sectional analysis of 211 patients with 967 dental implants showed significant positive effects of keratinized mucosa on bleeding index, BoP and plaque index. 23 Furthermore, a systematic review focused on effects of soft tissue health on development of periimplantitis has concluded that absence of adequate keratinized peri-implant mucosa associated with increased plaque accumulation, gingival inflammation and bleeding on probing. 24 The significant difference in keratinized mucosa height at test compared with control abutments in the study presented here was consistently observed from 6-week to 2-year follow-up. However, the lack of respective baseline data comprises a limitation of the study that may affect the interpretation of between-group differences during follow-up despite the split-mouth design and selection of similar sites for the placement of implants and abutments. Significant presence of keratinized mucosa at the lingual side of the abutments was always aimed for, which resulted in less keratinized mucosa at the buccal side in several cases after surgery. Thus, the height of the keratinized mucosa at the buccal side would seldom be half the total width measured before surgery and the exact height at the buccal side after surgery could not be determined beforehand. Measurements immediately after surgery would have been compromised due to tissue swelling. Therefore, the initial measurement of the keratinized mucosa height was at the 6-week follow-up. Notably, 17 subjects required more than the two implants and abutments as needed for the purpose of the study, and abutments with the control surface type were placed at these additional sites. Exploratory analysis of the height of keratinized mucosa at these additional control-type abutments showed no difference compared with the height of keratinized mucosa at the designated control abutments.
Consistent with the difference found between designated control and test abutments, also the height of keratinized mucosa at the additional sites was significantly lower than at the sites of the test abutments at Includes the subset of patients who received the additional "other" abutment with the control surface. There were no significant differences of marginal bone levels at permanent prosthesis insertion and 2-year follow-up. A communication between the jaw bone and the oral cavity will always start a remodeling process, most often resulting in loss of marginal bone.
With regard to the Brånemark System implants and two-stage surgery, this was formerly initiated at the abutment connection after 3 to 6 months of healing and registered on radiographs in relation to placement of the fixed prosthesis, as well as at the first annual check-up.
According to Adell et al 25 and later confirmed by Jimbo and Albrektsson 26 the loss of bone averaged 1.0 to 1.5 mm during the first year (bone level at the first implant thread) to be more or less stable during the years to come. In those days a different radiographic reference point was used, that is, the lower part of the polished neck, 0.8 mm from the fixture-abutment junction (FAJ). The motivation was that the polished neck would never present with osseointegration. Today, when using the same implant design, FAJ is mainly used as the reference point and will add 0.8 mm to the distance down to the first implant thread, resulting in a total distance of approximately 1.9 mm. 27 One must also consider that by using FAJ as the reference point, excessive marginal bone resorption may sometimes be registered without reflecting a true situation, when implants have been positioned with the polished neck above bone level. The studied implants of the current investigation were placed according to one-stage surgery and the bone remodeling process was initiated already at day one. Thus, after the first 6 weeks of healing most of the marginal bone loss had already occurred.
In addition to the lack of baseline data on keratinized mucosa as discussed above, the unblinded design of the study, particularly due to the different color of test and control abutments, may be considered as a relevant limitation. Furthermore, the broad inclusion criteria 
| CONCLUSION
Within the limitations of the study, we conclude that abutments with an anodized and nanostructured surface compared with a conventional, machined titanium surface had no significant effect on bacterial 
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